AstraZeneca Completes Acquisition of Ardea Biosciences
20 6월 2012 - 4:18PM
Dow Jones News
LONDON--Biopharmaceutical business AstraZeneca PLC (AZN.LN) said
Wednesday that on June 19 it completed its acquisition of San
Diego, California-based biotechnology company Ardea Biosciences,
Inc. (RDEA).
MAIN FACTS:
-Upon completion of the merger, each outstanding share of Ardea
common stock was cancelled and converted into the right to receive
32 dollars, in cash, without interest, and shares of Ardea common
stock ceased trading on the NASDAQ Global Select Market.
-AstraZeneca shares closed Tuesday at 2760 pence valuing the
company at 34.8 billion pounds.
-Write to Ian Walker at ian.walker@dowjones.com
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Ardea Biosciences, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Ardea Biosciences Inc. News Articles